Penumbra, Inc. (PEN) — Analysis Summary
Penumbra, Inc. (PEN) has a market cap of $12.54B with year-over-year revenue growth of +17.5%. Net margin stands at 12.7%. The stock trades at a P/E ratio of 73.3.
Key Takeaways
- Revenue changed +17.5% year-over-year
- Net margin of 12.7%
- P/E ratio of 73.3
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, PEN posted revenue growth of +17.5% and trades at a P/E of 73.3.
Penumbra, Inc. (PEN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
4,700
Headquarters
ALAMEDA, CA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.